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Abstract
Background: Many patients with suspected malaria in sub-Saharan Africa seek treatment from private providers,
but this sector suffers from sub-standard medicine dispensing practices. To improve the quality of care received for
presumptive malaria from the highly accessed private retail sector in western Kenya, subsidized pre-packaged
artemether-lumefantrine (AL) was provided to private retailers, together with a one day training for retail staff on
malaria diagnosis and treatment, job aids and community engagement activities.
Methods: The intervention was assessed using a cluster-randomized, controlled design. Provider and mystery-
shopper cross-sectional surveys were conducted at baseline and eight months post-intervention to assess provider
practices. Data were analysed based on cluster-level summaries, comparing control and intervention arms.
Results: On average, 564 retail outlets were interviewed per year. At follow-up, 43% of respondents reported that
at least one staff member had attended the training in the intervention arm. The intervention significantly
increased the percentage of providers knowing the first line treatment for uncomplicated malaria by 24.2% points
(confidence interval (CI): 14.8%, 33.6%; adjusted p=0.0001); the percentage of outlets stocking AL by 31.7% points
(CI: 22.0%, 41.3%; adjusted p=0.0001); and the percentage of providers prescribing AL for presumptive malaria by
23.6% points (CI: 18.7%, 28.6%; adjusted p=0.0001). Generally outlets that received training and job aids performed
better than those receiving one or none of these intervention components.
Conclusion: Overall, subsidizing ACT and retailer training can significantly increase the percentage of outlets
stocking and selling AL for the presumptive treatment of malaria, but further research is needed on strategies to
improve the provision of counselling advice to retail customers.
Keywords: Community case-management of malaria, Artemisinin-based combination therapy, Antimalarial subsidy
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Background
Artemisinin-based combination therapy (ACT) has been
incorporated into national policies for the treatment of
uncomplicated malaria in all Plasmodium falciparum-
endemic countries in Africa [1,2]. Many patients with
suspected malaria in sub-Saharan Africa seek treatment
from private providers [3-5], but this sector has been
associated with substandard practices, such as misdiag-
noses, poor counselling and incorrect dosing [4,6]. In
addition, private sector retail prices for ACT have been
high compared to those for less effective, but more
widely used monotherapy, such as amodiaquine or
sulphadoxine-pyrimethamine (SP) [7]. Barriers in the
private and public sectors to accessing ACT treatment
have contributed to the finding that less than 22% of
children with fever were treated with an ACT across six
African countries [8]. It is, therefore, important to inves-
tigate ways to improve the quality of malaria case-
management in the private sector. Attention has focused
on a range of strategies, including shopkeeper training,
pre-packaging of drugs, community education, and most
recently, ACT subsidies [9-11].
In Kenya, previous pilot studies have shown that inter-
ventions that included training of general shopkeepers
could improve malaria case-management [12-15]. How-
ever, these interventions were carried out when anti-
malarial monotherapies such as SP and amodiaquine
were still effective and were the first line treatment for
uncomplicated malaria. The introduction of AL as first
line treatment posed major challenges to the shopkeeper
training strategies since AL was less well-known than
the monotherapies, and required specific knowledge and
dispensing practices. Existing policies to train shop-
keepers on older monotherapies were no longer appro-
priate or likely to have a significant impact on coverage
of appropriate treatment. Here data are presented from
provider and mystery-shopper surveys conducted in
western Kenya, as part of a cluster-randomized,
controlled trial of an ACT subsidy programme, which
included shopkeeper training and community awareness
activities, to evaluate its impact on private sector ACT
availability, provider knowledge, and provider dispensing
practices.
Methods
Study sites
The study was conducted in three districts in western
Kenya (Busia, Butere-Mumias and Teso) where the first-
line treatment for uncomplicated malaria was the ACT
artemether-lumefantrine (AL). These areas were selected
because of the presence of a relatively active retail
market, and their high malaria endemicity [16]. Across
the three districts, the percentage of the population
living below the poverty line averaged 60% [17]. At the
time of the study, Butere-Mumias had 51 government
health facilities, Busia 39 and Teso 21, consisting of dis-
pensaries, health centres and one district hospital per
district (Noor, unpublished observations). All govern-
ment health facilities in Kenya are supposed to supply
AL free to patients, although stock-outs and unofficial
fees are common [18,19]. The three main types of retail
outlets supplying anti-malarials in Kenya were registered
and unregistered pharmacies (together termed special-
ized drug stores), and general stores. Registered pharma-
cies are generally rare in rural areas. Artemether-
lumefantrine was a prescription-only medicine, officially
available at registered health facilities and pharmacies
only, although in practice many prescription-only drugs
were dispensed without a prescription in pharmacies
and other retail outlets. At the time of the study, AL had
a retail price of around 6.16 US dollars (USD) (500
Kenya Shillings [KSH]) source of exchange rate: http://
www.exchangerate.com/. On 1st November 2008, one
USD was equivalent to 81.23 KSH), compared with an
average of around 0.37 USD for common, older anti-
malarials such as SP and amodiaquine. Malaria diagnosis
was predominantly presumptive, based on the presence
of fever, in both public and private health facilities
[20,21].
Study design
This study forms part of a cluster-randomized, con-
trolled trial, evaluating the impact of the ACT subsidy
intervention on effective malaria treatment of children
under five [22]. Data were collected both before (at base-
line) and after (at follow-up) the roll out of the interven-
tion and consisted of four main data collection activities:
household surveys, provider surveys, mystery-shopper
surveys, and focus group discussions. Community
randomization of rural sublocations is described in detail
elsewhere [22]. Nine sublocations were allocated to the
intervention arm, and nine to the control arm, with a
buffer zone of two sublocations between selected
sublocations. Due to the public information campaign
around the subsidized drugs in the intervention arm,
blinding was not possible for shopkeepers or data
collectors.
The intervention
The intervention was implemented by the Division of
Malaria Control (DOMC) of the Kenyan Ministry of
Public Health and Sanitation, Population Services
International (PSI), and the Pharmacy and Poisons
Board (PPB).
The three main intervention components were provision
of subsidized packs of paediatric AL to retail outlets,
training of retail outlet staff, and community awareness ac-
tivities. No interventions were implemented in the control
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arm. In both intervention and control arms the policy of
provision of free AL at government facilities continued un-
changed. At baseline, public sector AL stock-outs were
common, with only one third of facilities serving the study
areas stocking both children’s packs (six- and 12-tablet
packs) of AL, but by follow-up this figure had almost dou-
bled to 65% [19; Kangwana, unpublished observation]. In
2006/7 the government had carried out AL awareness cam-
paigns across the country, so both arms had previously re-
ceived some general information on the current malaria
treatment policy.
The intervention targeted retail outlets serving inter-
vention sublocations, which were identified through an
outlet census. Outlets were included in the census if
they were located in or on the borders of the interven-
tion sublocations and identified by key informants as
serving their populations. An initial list of retail outlets
was sourced from local public health officers, and
updated with input from local chiefs and subchiefs. The
list was further amended after visiting the study areas
with village elders, through the snowball technique [23]
where each shop visited was asked about the presence of
other outlets in their area, and by discussions with com-
munity members. Enumerated outlets were invited for
training if they had been functioning for a minimum
period of six months and were identified as selling
anti-malarials and/ or antipyretics during the past year.
Outlet staff attended a one-day, malaria-related training
between August and October 2008 covering clinical
diagnosis, treatment, adverse drug reactions, and patient
referral. Training materials were developed by the imple-
mentation team, building on those used previously for
shopkeeper training in Kenya [12].
From November 2008, subsidized AL was provided to
trained retail outlets in packs of six tablets (for children
aged three to 35 months) and 12 tablets (for children
aged 36 to 59 months). The AL was branded as Tibamal,
a pretested name derived from the Kiswahili words “Tiba
ya Malaria” meaning malaria cure, and came with pa-
tient instructions suitable for those with low literacy
levels. The PPB granted special dispensation for AL to
be dispensed over the counter in the intervention arm.
PSI sales staff delivered the treatment directly to trained
outlets on a monthly basis, at a wholesaler price of 0.10
USD per pack (both packs were the same price). The
outlets were instructed to sell the packs at a retail price
of 0.25 USD, which was printed on the drug packaging,
providing a 150% retailer mark-up, exceeding that of
amodiaquine and SP, which generally had retail mark-
ups of 50% to 100%.
Trained outlets were supplied with job aids to support
dispensing, consisting of a referral flow chart and dosing
guidelines. The main community awareness activities
began in March 2009, focusing on malaria symptoms,
Tibamal availability, and patient adherence. They consisted
of community leader workshops, community events; small
group discussions and outreach activities. Tibamal was also
advertised through posters and paintings on shops selling
the treatment, and through distribution of branded head-
scarves, tee shirts, and pens. A follow-up, supervisory visit
was made by the implementation team three months after
initial provision of Tibamal supplies to monitor outlet
practices.
Data collection
Data on retailer performance were collected through
provider surveys and mystery-shopper surveys, which
aimed to determine whether private sector retailers
could deliver AL to appropriate standards of quality for
the treatment of fever in children under five. The pro-
vider survey assessed the anti-malarials stocked, and
knowledge and stated practices of the provider related to
malaria treatment, such as knowledge of the first-line
anti-malarial, malaria symptoms, and advice to provide
when dispensing AL. The mystery-shopper survey
assessed patient-provider interactions, to provide infor-
mation on actual rather than self-reported provider
practice. Both data collection activities were conducted
at baseline (July-August 2008) and follow-up (July-Au-
gust 2009). The mystery-shopper survey was conducted
first, to avoid raising awareness by the shopkeepers of
the presence of the survey team. The sampling frame for
both surveys was based on the retail census carried out
in May 2008 and May 2009, described above. All outlets
that had been functioning for at least six months and
had sold an anti-malarial or antipyretic within the past
year were included in survey data collection.
For the provider survey, written consent was obtained
from shopkeepers at the time of the interview. For the
mystery-shopper survey, written consent was sought in
advance from all shopkeepers interviewed during the
retail census. At the time of the census, staff were in-
formed about the nature of the mystery-shopper survey,
but details on whether their shop was selected and the
date of the survey visit were not revealed. The gap be-
tween the census and the mystery-shopper survey was
just over a month.
Provider survey data were collected using a pretested
structured questionnaire administered to the shopkeeper
present at the time of the visit who was most responsible
for selling medication. In the mystery-shopper survey,
fieldworkers disguised themselves as local residents seek-
ing treatment for a child. All fieldworkers were trained
to present the following scenario to the shopkeeper: a
four-year-old child (weighing 15 kg), under their care
who has been suffering from a recurring fever for three
days, especially at night. The child had no other symp-
toms, and no medication had been given so far [13]. The
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fieldworker discreetly recorded the details of the inter-
action on a questionnaire away from the outlet, once the
interview was complete. All interviews were carried out
in each district’s local dialect.
Data analysis
Based on baseline values of the primary indicator ‘pro-
portion of outlets stocking any unexpired AL’ the study
sample size of nine clusters per arm and an average of
26 outlets per cluster was sufficient to detect a 20%
point difference at a 0.05 significance level and 80%
power [24].
Data were analysed in STATA version 11 (College
Station, TX, USA) by a two-stage process, with baseline
and follow-up data analysed separately [25]. In the first
stage a summary cluster measure was obtained for each
cluster. The second stage involved comparing the sets of
cluster-specific measures in control and intervention
arms at follow-up using the unpaired t-test [25]. A crude
analysis was carried out on the cluster summaries using
the simple two-tailed t-test to obtain the mean percent-
age difference between the intervention and control
arms, 95% confidence intervals (CIs) and standard devia-
tions (SDs) for each outcome. In addition, an adjusted
analysis was carried out at follow-up using an individual
level logistic regression run on the pooled data set (con-
trol and intervention arms). To control for potential
confounders the covariates considered were outlet type
(specialized drug store or general store), distance of shop
to nearest road, whether any staff had clinically related
training, and district. All covariates significant at a
p-value of <0.2 were retained in the regression model.
Baseline values for the outcome in question were also
included as covariates if a difference of 5% points or
more was observed between the arms at baseline. The
intervention status of the cluster was not included in the
logistic regression model. Rather, the regression model
provided the predicted outcome in the absence of the
intervention effect. Mean predicted and observed out-
comes were obtained per cluster and residuals were
obtained by subtracting the predicted outcomes from
those observed in each cluster. The t-test was used on
these residuals to assess the difference in the residuals,
which represents the intervention effect adjusted for the
covariates included in the logistic regression model. The
t-test was used for both crude and adjusted analyses, as
it has been shown to be highly robust even for small
numbers of clusters [25]. For indicators concerning the
‘percentage of outlets providing correct dispensing ad-
vice for AL’ in the mystery-shopper survey, the Fisher’s
exact test was used to calculate p values, due to the
small number of observations in the denominator in the
control arm [26]. Distances from retail outlets to nearest
roads were calculated using the Euclidean tool in
ArcGIS (ESRI, Redlands, CA, USA) spatial analysis tool.
Since the intervention was delivered under operational
rather than ideal conditions, outlets in the intervention
arm varied in their level of exposure to the intervention.
Specifically, not all outlets in the intervention arm were
trained, and not all outlets received job aids. The ana-
lysis was therefore conducted on both an intention to
treat and per-protocol analysis basis. In the intention to
treat analysis outlets were analysed in the clusters to
which they were randomized, regardless of whether they
received the intervention. In the per-protocol analysis
only outlets in the intervention cluster that received the
intervention were included. Two levels of intensity of
intervention were considered: outlets that received the
Tibamal training, termed ‘trained’, and those that re-
ceived the Tibamal training and had a Tibamal job aid in
the outlet at the time of the interview, termed ‘trained
with job aid’. No hypothesis testing was carried out to
evaluate the statistical significance in differences ob-
served between these subsamples and the population of
all outlets in the intervention arm as the groups repre-
sent overlapping categories (some outlets were present
in two or three of these groups). In both the provider
and mystery-shopper surveys, at baseline and also at
follow-up, less than 10% of outlets were not interviewed
either because the respondent refused to be interviewed
or the outlet was closed during visits.
Ethical approval
Ethical approval was obtained from the Kenya Medical
Research Institute (KEMRI) Ethical Review Committee
(#1361), the Kenya Pharmacy and Poisons Board Ethical
Committee for Clinical Trials (# PPB/ECCT/08/07), and
the London School of Hygiene and Tropical Medicine
Ethical Review Committee (# 5288). The study is registered
with Current Controlled Trials (# ISRCTN59275137).
Results
Outlet characteristics
The number of outlets meeting the census selection cri-
teria was 295 in the control arm and 225 in the inter-
vention arm at baseline, and 369 and 351 respectively at
follow-up. For the provider survey, a total of 468 outlets
were successfully interviewed at baseline and 639 at
follow-up; and for the mystery-shopper survey, 499 at
baseline and 653 at follow-up (Table 1). The changes in
number of outlets surveyed at baseline compared to
follow-up were partly due to the fluidity of the market,
where over time some shops would close temporarily or
permanently, and new ones open. In addition, there is a
possibility that fieldworkers became better at identifying
outlets at follow-up. In both surveys, general stores con-
stituted over 70% of shops evaluated at baseline and
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Table 1 Characteristics of staff interviewed in the provider survey (cluster summaries from the 9 intervention and 9 control clusters)
Baseline Follow up
Control%
(SD) n
Intervention%
(SD) n
Control%
(SD) n
All Intervention%
(SD) n
Trained Intervention%
(SD) n
Trained & Job aid Intervention%
(SD) n
No. of outlets 263 205 319 320 154 62
Outlet type:
Specialized drug stores 19.6 (8.4) 49 26.2 (16.3) 53 17.8 (7.3) 56 22.9 (8.7) 74 31.1 (5.5) 49 33.9 (28.6) 21
General stores 80.4 (8.4) 214 73.8 (16.3) 152 81.9 (7.6) 262 77.1 (8.7) 246 68.8 (5.5) 105 66.1 (28.6) 41
Other 0 (0) 0 0 (0) 0 0.3 (1.0) 1 0 (0) 0 0 (0) 0 0 (0) 0
Outlets with at least one member of staff usually serving customers with the following characteristics:
Primary education complete and above 79.2 (9.1) 211 76.8 (17.0) 159 74.8 (11.5) 237 68.7 (13.1) 222 72.6 (18.2) 111 70.4 (23.9) 42
Any clinical training1 21.3 (8.1) 55 23.5 (18.8) 51 15.7 (6.7) 50 18.9 (8.4) 63 24.3 (6.3) 40 27.4 (28.2) 16
Below 16 years 3.5 (5.8) 8 3.3 (3.5) 7 3.4 (3.5) 10 2.1 (2.7) 6 2.1 (4.2) 4 2.7 (5.5) 2
Distance to nearest road:
Metres (SD) 187.7 (123.8) 326.6 (286.9) 201.6 (121.5) 231.4 (98.8) 256.3 (156.7) 300.6 (213.6)
n=numerator (denominator for all indicators is shown under No. of outlets).
1 Any clinical related training consists of: pharmacy, nurse and medical doctor related training; Pharmacy related training includes pharmacy studied to a certificate or diploma level; Nurse related training includes
studying nursing to a certificate level (nurse aid) and diploma level; Medical doctor training includes clinical officer who studied medicine to a diploma level.
Note: In the mystery shopper survey, a total of 499 outlets were successfully interviewed at baseline, 284 and 215 in control and intervention arms respectively, and 653 outlets at follow-up, 336 in the control and 317
in the intervention arm.
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follow-up, with specialized drug shops making up almost
all the remainder (Table 1). The mean number of staff
serving customers was just under two per outlet at base-
line and follow-up. The percentage of outlets with staff
with any clinical training, who usually or occasionally
served customers, ranged from 15.7% at follow-up in the
control arm to 23.5% at baseline in the intervention arm
(Table 1). When broken down by outlet type, this
averaged 63.6% and 75.7% in specialized drug stores and
9.6% and 4.5% in general stores, across both arms at
baseline and follow-up, respectively. Less than 4% of
outlets had a child below 16 years of age usually or occa-
sionally serving customers. The mean distance of retail
outlets to the nearest road (any road excluding foot-
paths) was 188 and 327 m in the control and interven-
tion arms respectively at baseline, and 203 and 231
respectively at follow-up (Table 1).
Within the subgroup of outlets that had received
Tibamal training (trained) at follow-up, 31.1% were
specialized drug stores, and in outlets that had received
training and had a Tibamal job aid (trained with job aid)
33.9% were specialized drug stores. Outlet characteristics
within the trained and trained with job aid subgroups
were similar to those for all outlets in the intervention
arm at follow-up (Table 1), although specialized drug
stores were slightly more common among the trained
and trained with job aid outlets than among all interven-
tion outlets. The characteristics of outlets and staff
surveyed in the mystery-shopper survey were similar to
those in the provider survey (data not shown).
Exposure to the intervention
In the provider survey 71.3% of respondents at baseline
and 77.0% at follow-up had heard of AL, across the
arms. At follow-up, 13.9% and 91.6% of respondents
were aware of Tibamal, in the control and intervention
arms, respectively. Also at follow-up, 43.1% of respondents
in the intervention arm reported having at least one
member of staff that had attended the Tibamal training,
compared to only 1.0% in the control arm. Of outlets in the
intervention arm, 67 (22.1%) were in possession of a
Tibamal job aid and 62 (20.5%) had at least one trained staff
member and a Tibamal job aid. No outlet in the control
arm had a job aid.
Anti-malarial availability and storage
During the provider survey, unexpired AL was found in
less than 3% of outlets at baseline, across both arms. AL
stocking had increased by follow-up to 36.8% in the
intervention arm, but remained low at 5.2% in the con-
trol arm (Table 2). The difference between the arms at
follow-up was significant (adjusted p=0.0001, difference
in means: 31.7%; 95%CI: 22.0, 41.3). Tibamal constituted
around 95% of all AL available in the intervention arm
at follow-up, with no outlets stocking Tibamal in the
control arm. Less than 3% of outlets were observed with
stocks of any other ACT in both arms and at both time
points. At baseline 52.8% of outlets in the control arm
stocked a non-ACT anti-malarial (SP, amodiaquine, arte-
misinin monotherapy, quinine or chloroquine) and
63.7% in the intervention arm. The availability of non-
ACT fell by 13 percentage points and 24 percentage
points in the control and intervention arms respectively,
from baseline to follow-up, though the difference in
availability between the arms at follow-up was not sig-
nificant (adjusted p value=0.5187, difference in means:
0.4%; 95%CI: -7.6, 8.5) (Table 2). The availability of arte-
misinin monotherapy remained below 5% at baseline
and follow-up, and across the arms.
Among the subgroup of trained outlets 65.7% stocked
AL at follow-up, and among the subgroup of trained
with job aid outlets, 76.8%, 29 and 40 percentage points
higher than among all intervention arm outlets. Avail-
ability of non-ACT was also higher in the two subgroups
when compared to all outlets in the intervention arm at
follow-up. Nine intervention outlets stocked Tibamal
even though none of the staff were reported to have
attended the training. It was not clear whether this was
because the staff member who had attended training
was not present on the day of the survey and other staff
were not aware they had attended; whether there was
some “leakage” of the subsidized drug to untrained
shops; or whether the trained staff were no longer work-
ing in the outlet.
Outlets stocking AL were assessed to see if the treat-
ment was stored appropriately. The definition of ‘appro-
priately’ was all AL packs kept off the floor, out of direct
sunlight, in a dry area and with packaging intact. At
follow-up, 78.8% and 81.9% of outlets were observed to
be storing all AL stocks appropriately in the control and
intervention arms, respectively. The percentages were
similar in trained outlets and trained with job aid outlets
and in all intervention outlets. Expired AL stock was
found in less than 1% of outlets in both arms and time
points.
Provider knowledge
Data from the provider survey showed that at baseline
37.8% of respondents in the control arm and 34.3% in
the intervention arm were able to identify AL as the
first-line treatment for uncomplicated malaria. At
follow-up, this had improved in both arms, but was sig-
nificantly greater in the intervention arm compared to
the control arm (adjusted p value = 0.0001, difference in
means: 24.2%; 95%CI: 14.8, 33.6) (Table 3). Fever, as a
symptom of uncomplicated malaria was mentioned by
67.3% of respondents at baseline, across both arms, and
increased to 74.3% and 84.0% in the control and
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intervention arms respectively. Respondents were asked
where they would recommend a four year-old child
suspected to be suffering from complicated malaria to
seek treatment first. Over 70% of respondents correctly
said they would refer the child directly to a health facil-
ity at baseline, in both arms. This increased to more
than 80% at follow-up, across both arms. For all the
knowledge indicators described above, respondents from
the subgroup of trained outlets performed better than
the population of all outlets in the intervention arm at
follow-up. Outlets that were trained with job aid
performed better than trained outlets with the greatest
difference of 10.7 percentage points (82.7% trained:
93.4% trained with job aid) observed in the percentage
knowing the first-line anti-malarial (Table 3).
In the provider survey, respondents were asked about
the advice they would give to a caregiver purchasing any
brand of AL for their four year-old child. Respondents
were asked to advise on AL administration, what to do if
the child vomits, what to do if the child does not im-
prove, and foods to administer with the medication
(Table 3). Across all the advice points there was signifi-
cantly higher knowledge (p<0.005) in the intervention arm,
compared to the control arm, at follow-up. The greatest
difference was observed in advice to give ‘if the child does
not get better’; at baseline 47.7% of respondents knew the
correct advice, and at follow-up 39.8% and 66.0% in the
control and intervention arms respectively (adjusted p
value=0.0001; difference in means: 26.2%; 95%CI: 15.0,
37.4). The least improvement was observed in ‘what to
do if the child vomits after taking the medication’,
where no respondents knew the correct response at base-
line, and at follow-up this increased to only 1.5% and 9.4%
in the control and intervention arms respectively (adjusted
p value: 0.0027; difference in means 7.9%; 95%CI: 2.9,
12.9). Across these advice indicators, the subgroup of
trained outlets performed better than the population of all
outlets in the intervention arm, with the greatest differ-
ence observed in ‘what to do if the child does not get bet-
ter’ where there was a 22.8 percentage point difference
(66.0% all outlets; 88.8% trained outlets). The least im-
provement was observed in ‘what to do if the child vomits’
where there was a 7.5 percentage point difference (9.4% all
outlets; 16.9% trained outlets). Trained outlets with job
aids performed better than trained outlets, with the
greatest difference in the correct advice on foods to give
the child (45.1% trained outlets; 61.1% trained with job
aid), and the least difference in what to do if the child
vomits (16.9% trained outlets; 18.2% trained outlets with
job aids) (Table 3).
Table 2 Availability of anti-malarials (provider survey) (cluster summaries from the 9 intervention and 9 control clusters)
Availability of anti-malarials: Control% (SD) n/d Intervention% (SD) n/d Difference in means (95%CI) P value Unadjusted Adjusted
Any AL (unexpired):
Baseline 0.5 (1.2) 2/263 1.5 (3.2) 3/205
Follow up 5.2 (4.0) 18/319 36.8 (13.1) 117/320 31.7 (22.0, 41.3) 0.0001 0.00011
Tibamal trained - 65.7 (16.1) 103/154
Tibamal trained & job aid - 76.8 (32.4) 50/62
Tibamal (unexpired):
Baseline - -
Follow up 0 (0) 0/319 35.1 (12.3) 111/320 35.1 (26.4, 43.8) 0.0001 0.00012
Tibamal trained - 65.3 (15.6) 102/154
Tibamal trained & job aid - 76.8 (32.4) 50/62
Other ACT:
Baseline 0.8 (1.6) 2/263 0 (0) 0/205
Follow up 2.1 (2.8) 7/319 0.4 (1.1) 1/320 −1.7 (−3.9, 0.4) 0.1058 0.05802
Tibamal trained - 0.5 (1.6) 1/154
Tibamal trained & job aid - 1.1 (3.3) 1/62
Non-ACT therapy:
Baseline 52.8 (12.0) 140/263 63.7 (10.4) 130/205
Follow up 39.6 (10.0) 128/319 40.0 (5.5) 127/320 0.4 (−7.6, 8.5) 0.9082 0.51873
Tibamal trained - 54.3 (13.5) 80/154
Tibamal trained & job aid - 53.8 (28.1) 35/62
n numerator, d denominator, SD standard deviation, CI confidence interval.
1 adjusted for distance to nearest road; 2 adjusted for outlet type and district; 3 adjusted for outlet type, distance to nearest road and clinical training.
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Provider behaviour
At baseline anti-malarials were dispensed to 25.2% of mys-
tery shoppers in the control arm and 40.7% in the interven-
tion arm, and this was little changed at endline, with 20.2%
in the control arm and 40.3% in the intervention arm
(Table 4). This remained fairly similar at follow-up. The
reasons for the higher frequency of anti-malarial dispens-
ing in the intervention arm at both time points were not
clear. Less than 1% of mystery shoppers were sold AL at
baseline, across both arms. At follow-up, sales of AL
remained low at 1.8% in the control arm, but were signifi-
cantly higher at 25.4% in the intervention arm (adjusted
Table 3 Provider knowledge (provider survey) (cluster summaries from the 9 intervention and 9 control clusters)
Control%
(SD) n/d
Intervention%
(SD) n/d
Difference in means
(95%CI)
P value
Unadjusted Adjusted
Percentage knowing the first line anti-malarial for uncomplicated malaria:
Baseline 37.8 (9.0) 103/263 34.3 (16.6) 70/205
Follow up 46.9 (7.9) 151/319 71.1 (10.9) 227/320 24.2 (14.8, 33.6) 0.0001 0.00011
Tibamal trained - 82.7 (9.8) 129/154
Tibamal trained & job aid - 93.4 (8.2) 58/62
Percentage knowing fever as a symptom of uncomplicated malaria:
Baseline 66.4 (10.7) 179/263 68.1 (11.6) 142/205
Follow up 74.3 (8.0) 238/319 84.0 (6.5) 268/320 9.7 (2.4,17.0) 0.0124 0.01372
Tibamal trained - 95.2 (7.7) 136/154
Tibamal trained & job aid - 96.9 (8.8) 53/62
Percentage that would refer a suspected case of complicated malaria in a four year old child to a health facility:
Baseline 74.1 (12.0) 194/263 75.9 (7.3) 155/205
Follow up 83.7 (6.4) 266/319 86.9 (4.0) 278/320 3.2 (−2.1,8.6) 0.2148 0.06941
Tibamal trained - 89.6 (7.8) 138/154
Tibamal trained & job aid - 90.9 (16.2) 58/62
Percentage knowing correct dispensing practices of AL:
AL administration
Baseline 0.7 (1.4) 2/263 0 (0) 0/205
Follow up 1.2 (1.5) 4/319 13.0 (11.3) 44/320 11.7 (3.7, 19.8) 0.0070 0.00263
Tibamal trained - 21.4 (18.3) 36/154
Tibamal trained & job aid - 30.7 (22.6) 16/62
What to do if the child vomits after taking the medication
Baseline 0 (0) 0/263 0 (0) 0/205
Follow up 1.5 (2.4) 4/319 9.4 (6.7) 30/320 7.9 (2.9, 12.9) 0.0043 0.00274
Tibamal trained - 16.9 (10.8) 27/154
Tibamal trained & job aid - 18.2 (18.8) 15/62
What to do if the child does not get better
Baseline 46.4 (10.0) 120/263 49.0 (12.6) 99/205
Follow up 39.8 (13.6) 127/319 66.0 (8.3) 209/320 26.2 (15.0, 37.4) 0.0001 0.00014
Tibamal trained - 88.8 (7.1) 136/154
Tibamal trained & job aid - 97.9 (4.2) 60/62
Food to give the child with AL
Baseline 8.3 (5.7) 22/263 8.6 (9.8) 18/205
Follow up 6.3 (5.9) 20/319 27.4 (11.2) 86/320 21.1 (12.1, 30.0) 0.0001 0.00014
Tibamal trained - 45.1 (5.0) 71/154
Tibamal trained & job aid - 61.1 (23.1) 35/62
n numerator, d denominator, SD standard deviation, CI confidence interval.
1adjusted for outlet type and district; 2adjusted for outlet type; 3 adjusted for district and clinical training; 4adjusted for outlet type and district.
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p=<0.0001; difference in means: 23.6%; 95%CI: 18.7, 28.6).
If only those intervention outlets are considered which had
a staff member who had attended Tibamal training, and
had Tibamal in stock during the provider survey, 60% dis-
pensed Tibamal to the mystery shoppers. Of the 40% (39
outlets) that did not dispense Tibamal, 16 (mainly general
stores) referred the mystery shopper to a specialized drug
store, 13 (mainly drug stores) dispensed another anti-
malarial (mainly SP), 6 dispensed an antipyretic only, 3 re-
ferred to a general shop, and 1 referred to a health facility.
Table 4 Provider practices (mystery shopper survey) (cluster summaries from the 9 intervention and 9 control clusters)
Control%
(SD) n/d
Intervention%
(SD) n/d
Difference in means
(95%CI)
P value
Unadjusted Adjusted
Percentage of outlets dispensing any anti-malarial:
Baseline 25.2 (8.9) (74/284) 40.7 (9.3) (88/215)
Follow up 20.2 (3.7) (68/336) 40.3 (6.5) (127/317) 20.1 (14.8, 25.4) 0.0001 0.02601
Tibamal trained 56.6 (23.0) (88/144)
Tibamal trained & job aid 70.8 (30.0) (37/58)
Percentage of outlets dispensing any AL:
Baseline 0.5 (1.6) (2/284) 0.0 (0) (0/215)
Follow up 1.8 (1.3) (6/336) 25.4 (6.9) (77/317) 23.6 (18.7, 28.6) 0.0001 0.00012
Tibamal trained 43.3 (18.9) (67/144)
Tibamal trained & job aid 62.7 (31.0) (31/58)
Percentage of outlets asking about at least one danger sign:
Baseline 26.5 (14.1) (21/284) 21.6 (12.4) (14/215)
Follow up 27.4 (10.7) (90/336) 33.3 (14.2) (97/317) 4.9 (−7.9, 17.7) 0.4295 0.26673
Tibamal trained 46.3 (25.5) (58/144)
Tibamal trained & job aid 51.3 (30.0) (28/58)
Percentage of outlets providing the correct dispensing advice for AL:
AL administration
Baseline 0.0 (0) (0/2) 0.0 (0) (0/0)
Follow up 0.0 (0) (0/6) 31.3 (16.3) (24/77) 31.3 (16.8, 45.8) 0.175
Tibamal trained 34.2 (18.0) (23/67)
Tibamal trained & job aid 45.2 (30.5) (12/31)
What to do if the child vomits after taking the medication
Baseline 0.0 (0) (0/2) 0.0 (0) (0/0)
Follow up 0.0 (0) (0/6) 2.5 (3.9) (2/77) 2.5 (−1.9, 6.8) 1.000
Tibamal trained 2.8 (5.7) (2/67)
Tibamal trained & job aid 4.4 (8.8) (2/31)
What to do if the child does not get better
Baseline 0.5 (1.6) (1/2) 0.0 (0) (0/0)
Follow up 0.0 (0) (0/6) 35.3 (13.1) (26/77) 35.3 (23.6, 47.1) 0.170
Tibamal trained 37.7 (12.6) (24/67)
Tibamal trained & job aid 38.9 (24.1) (14/31)
Food to give the child with AL
Baseline 0.0 (0) (0/2) 0.0 (0) (0/0)
Follow up 0.0 (0) (0/6) 13.7 (14.4) (9/77) 13.7 (0.8, 26.6) 1.000
Tibamal trained 13.3 (14.2) (8/67)
Tibamal trained & job aid 11.9 (14.8) (5/31)
1adjusted for outlet type and clinical training; 2adjusted for outlet type; 3adjusted for district and outlet type.
n numerator, d denominator, SD standard deviation, CI confidence interval.
Note: In the mystery shopper survey, a total of 499 outlets were successfully interviewed at baseline, 284 and 215 in control and intervention arms respectively,
and 653 outlets at follow-up, 336 in the control and 317 in the intervention arm.
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An average of 24.5% of respondents across both arms
asked their clients whether the child had at least one
danger sign at baseline. This improved slightly in the inter-
vention arm at follow-up, however the difference between
the arms was not statistically significant (adjusted p
value=0.2667; difference in means 4.9%; 95% CI: -7.9, 17.7).
For both of these provider-behaviour indicators trained
outlets performed better than all outlets in the intervention
arm, with the greatest difference observed in outlets
dispensing AL (25.4% all outlets; 43.3% trained outlets).
Similarly, trained outlets with job aids performed better
than trained outlets, with the greatest difference also ob-
served in dispensing of AL (43.3% trained outlets; 62.7%
trained with job aid).
Less than 1% of providers gave correct dispensing advice
for AL on any of the counselling points at baseline, across
both arms. At follow-up there were improvements in advice
in the intervention arm, but the differences between the
arms were not significant for any counselling indicators
related to AL dispensing. The greatest difference was ob-
served in what to do if the child does not get better, which
remained 0% in the control arm compared with 35.3% in
the intervention arm (difference in means: 35.3%; 95% CI:
23.6, 47.1). Trained outlets performed better than all outlets
in the intervention arm on advice on administration of AL,
and what to do if the child does not get better. Little differ-
ence was observed between the groups in what to do if the
child vomits, and foods to give the child. Trained outlets
with job aids performed better than trained outlets in all
counselling points apart from on advice on foods to give
the child.
Cost to consumers of artemether-lumefantrine
In the mystery-shopper survey, at baseline there were
only two doses of AL sold, at a cost of 2.46 and 2.22
USD. At follow-up, the 12 tab Tibamal was sold at a
median price of 0.25 USD (IQR: 20–20), which was the
recommended retail price. Of those not paying the
recommended price, two paid 0.37 USD, another two
paid 0.49 USD because of buying two packs of the six-
tab to meet the required dose, and one paid 0.74 USD.
Discussion
Before discussing the results in more detail a number of
limitations in the provider and mystery-shopper surveys
should be highlighted. Shops that had undergone
Tibamal training were identified by asking the respond-
ent if any of the staff had attended the training, but it is
possible that some responses were inaccurate due to re-
call bias or lack of awareness of training of fellow staff
members. In addition, given the prior consent process, it
is also possible that retailers were suspicious and there-
fore altered their practice and the advice they gave to
the mystery shopper. However, if this were the case then
the data would display ‘best practice’ of providers, while
still showing considerable room for improvement, espe-
cially in areas such as the provision of appropriate coun-
selling. In the scenario, the mystery shoppers waited for
the retailer to recommend treatment and paid whatever
price they were asked to. Other data (Kangwana and
colleagues, unpublished observations from Tibamal
focus group discussions and provider survey reports)
suggest that in practice the consumer often asks for a
specific treatment instead of the provider recommending
it, so real-life interactions may be somewhat different. It
is also possible that there was some contamination of
the control arm outlets, which could have heard some of
the communication activities. However, results indicated
that such exposure was low, with only 1% of control arm
respondents saying that they had attended the Tibamal
training, 14% having heard of Tibamal, and no outlets
stocking Tibamal.
The intervention was able to significantly improve the
percentage of outlets stocking AL, and more than 90%
of the AL available at follow-up in the intervention arm
was Tibamal. This indicates a willingness of shopkeepers
to take part in the intervention and make the treatment
available in their outlets. The intervention had an effect
on most provider knowledge indicators. Significantly
more providers in the intervention arm compared to the
control arm knew AL was the first-line treatment for
uncomplicated malaria and knew fever as a symptom of
uncomplicated malaria. Providers were also more
knowledgeable on correct dispensing practices for AL,
than those in the control arm. However, although the
difference observed between the arms was significant,
there remains a need for renewed effort to improve
these components of knowledge and prescription. For
example, for the scenario of ‘what to do if the child does
not get better’, only 66% of providers could give the
correct response. In addition, findings from the mystery-
shopper survey revealed that knowledge was not always
transferred into practice, since no significant improve-
ments were observed in any of the four appropriate
counselling indicators.
The mystery-shopper survey revealed that the inter-
vention not only encouraged shopkeepers to stock AL
but also significantly encouraged them to dispense AL to
clinically diagnosed cases of uncomplicated malaria. This
is in line with findings from the household surveys,
which showed that a significantly greater percentage of
febrile children in the intervention arm were treated
with AL compared to the control arm at follow-up [22].
The findings in this paper on changes in provider behav-
iour also serve to strengthen the claim that the changes
observed in the household survey were very likely due to
the Tibamal intervention. Encouragingly, the mystery shop-
per data showed providers adhering to the recommended
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retail price of Tibamal. Findings from the household survey
also revealed that >95% of caregivers purchased
Tibamal at its recommended retail price [22]. Printing
of the recommended price on Tibamal packaging as
well as making consumers aware of the subsidy
through the community activities may have contrib-
uted to providers not inflating Tibamal prices. Also,
the way in which the pricing was structured meant
that even with the subsidy, the retailer mark-up would
be greater than for other more commonly prescribed
anti-malarials, which may have facilitated both stocking
of Tibamal by retailers and appropriate pricing.
The intervention did not significantly increase the per-
centage of providers that would refer complicated cases
of malaria directly to a health facility. The data show
that even without the intervention, around 80% of shop-
keepers stated that they would automatically refer these
cases to a health facility, but since immediate specialized
care is required for complicated cases, one would hope
to see a referral rate of close to 100%. The intervention
was also not able to significantly increase the percentage
of providers asking for at least one danger sign, an im-
portant way of identifying severe cases. It could be that
providers instead tended to rely on the consumer to pro-
vide all the necessary information without being probed.
Identifying and implementing ways to improve enquiries
about danger signs is therefore important, in addition to
providing caregivers with the knowledge of when to by-
pass the retail sector and go straight to a health facility.
Although the intervention improved the share of AL
among mystery-shopper purchases it had no significant
impact on decreasing the availability of non-ACT in out-
lets. There was a decline in non-ACT availability at
follow-up, but this was observed in both arms and was
thought to be as a result of a government directive to
halt the production and supply of less effective mono-
therapy at the time of the survey. Availability of artemi-
sinin monotherapy was not a concern, with less than 5%
of outlets stocking this treatment, probably due to low
demand as a result of its high cost compared to other
anti-malarial monotherapy [27].
Overall, it seemed that the greater exposure shop-
keepers had to all components in the intervention,
the better they tended to perform. Outlets that had
received training seemed to perform better than all
outlets in the intervention arm, and outlets that had
received both training and job aids seemed to per-
form better than outlets just exposed to training. This
shows the importance of ensuring that implementa-
tion of the intervention is as ‘ideal’ as possible [28];
had higher coverage of training and job aids been
achieved, even more substantial improvements in pro-
vider behaviour and treatment coverage would likely
have been achieved.
These findings are of particular importance given the
current roll out of similar ACT subsidies under the
Affordable Medicines Facility - malaria (AMFm) on a
national scale in Kenya and seven other countries, also
accompanied by training and communications activities
[29]. In Kenya AMFm training of retail providers was
limited to registered pharmacists who were the only
retailers officially allowed to stock the AMFm subsidized
product, although in practice it was widely available in
unregistered pharmacies [30]. By demonstrating variation
in performance in relation to intervention intensity, and
highlighting areas of particularly weak provision, these
results can be used to identify potential strategies to en-
hance provision of subsidized ACT under AMFm and
other similar subsidy mechanisms.
The authors of this paper are not aware of any other
studies that explore the effect of an intervention
including an ACT subsidy on the performance of pri-
vate sector retailers in the treatment of presumptive
malaria. Several studies in sub-Saharan Africa have
however evaluated the effect of other interventions to
improve the quality of care received from the retail
sector in the treatment of presumptive malaria, mostly
with anti-malarial monotherapy. The majority of the
interventions included training of either providers
or users, and combined this with other supporting
activities such as provision of job aids, follow-up mon-
itoring and provision of prepackaged anti-malarial
treatment with pictorials to guide administration. The
outcomes of the interventions varied between studies but
the majority showed positive outcomes. Overall the inter-
ventions were able to improve provider knowledge on signs
and symptoms of malaria [31,32], and the proportion of
providers giving correct treatment and dose [14,33]. Some
interventions increased provision of correct advice on ad-
ministration [12,31], and asking for danger signs [31]. Inter-
ventions were also able to improve the availability of anti-
malarials in outlets [15,31]. Studies differed in their design,
data analysis techniques used and the type of outcome
measures used. Few studies carried out hypothesis testing
on their outcome results so it is difficult to interpret the
importance of any observed differences, and some studies
had limitations, for example very small sample sizes or no
appropriate comparison group. All these factors make it
difficult to make a direct comparison of outcomes in these
studies with the data presented here.
Exploration of the context in which the survey took place,
together with interviews with participants in the interven-
tion through focus group discussions (Kedenge and col-
leagues, unpublished observations from the Tibamal focus
group discussion report), have provided some insight into
the findings and how the results could have been further
improved. At follow-up, only 43% of outlets in the interven-
tion arm were identified as trained. Several possible reasons
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were given including that some businesses trained at base-
line had closed due to lack of capital; some businesses
relocated to other areas or had changed their type of busi-
ness, for example, from a general store to a bicycle spare
part shop. Also, recently opened but untrained shops had
not had the opportunity to be trained. This highlights the
need to hold regular courses to ensure that a well-trained
cadre of shopkeepers is maintained. In addition some pro-
viders thought that the training should have been longer,
refresher courses should have been included and the train-
ing could have better catered for illiterate shopkeepers. Fur-
thermore in response to the low percentage of patients
being counselled, some shopkeepers were said to work in a
very busy environment, having to attend to more than one
customer at a time, making it difficult to discuss these is-
sues with caregivers in any detail. As this is unlikely to
change, this highlights the merits of also providing this in-
formation directly to consumers through communication
activities.
Care should be taken when extrapolating or generalising
the findings of this pilot to other areas. Since Tibamal was
being supplied directly to outlets, there is the possibility
that monthly contact with PSI staff distributing AL may
have had the effect of influencing providers to work at
their best. Other factors affecting the generalizability
of these findings have been discussed by Kangwana
et al. [22].
Finally, the World Health Organization now recom-
mends that all suspected cases of malaria should be
parasitologically diagnosed before treatment, where diag-
nostics are available [1]. Therefore further research is
required into understanding how diagnostics will change
provider practices, and assessing strategies to ensure
diagnostics are used appropriately and supplied at an
affordable price.
Conclusion
The private sector remains a preferred source of anti-
malarial treatment in much of sub-Saharan Africa, in-
cluding Kenya. It is, therefore, important to support and
enable providers to provide appropriate and rational
management of malaria. This study has shown how an
intervention comprising of subsidized pre-packaged AL,
retailer training and community awareness activities can
improve certain aspects of provider knowledge and prac-
tices of presumptive malaria treatment.
The intervention significantly increased provider
awareness of the government’s recommended first-line
treatment for uncomplicated malaria, and along with
granting of over-the-counter status to AL, significantly
increased its availability. The intervention also signifi-
cantly increased the percentage of providers recommending
and dispensing AL, and encouraged providers to pass on
the subsidy to customers, making the treatment more af-
fordable. Further research is needed to improve aspects of
care where the intervention had minimal impact, particu-
larly provider knowledge and behaviour around danger
signs of malaria, and counselling practices.
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